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Abstract 
 
Objective. Oral estrogen therapy increases venous thromboembolism risk among 
postmenopausal women. Although recent data showed transdermal estrogens may 
be safe with respect to thrombotic risk, the impact of the route of estrogens 
administration and concomitant progestogens is not fully established. 
Methods and results. We used data from the E3N French prospective cohort of 
women born between 1925 and 1950 and biennially followed by questionnaires from 
1990. Study population consisted of 80,308 postmenopausal women (average follow-
up:10.1 years) including 549 documented idiopathic first venous thromboembolism. 
Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox 
proportional models. Compared to never-users, past-users of hormone therapy had 
no increased thrombotic risk (HR=1.1;95%CI:0.8-1.5). Oral not transdermal 
estrogens were associated with increased thrombotic risk (HR=1.7;95%CI:1.1-2.8 
and HR=1.1;95%CI:0.8-1.8; homogeneity: p=0.01). The thrombotic risk significantly 
differed by concomitant progestogens type (homogeneity: p<0.01): there was no 
significant association with progesterone, pregnanes and nortestosterones 
(HR=0.9;95%CI:0.6-1.5, HR=1.3;95%CI:0.9-2.0 and HR=1.4;95%CI:0.7-2.4). 
However, norpregnanes were associated with increased thrombotic risk 
(HR=1.8;95%CI:1.2-2.7).  
Conclusions. In this large study, we found that route of estrogen administration and 
concomitant progestogens type are two important determinants of thrombotic risk 
among postmenopausal women using hormone therapy. Transdermal estrogens 
alone or combined with progesterone might be safe with respect to thrombotic risk. 
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Condensed abstract 
 
We assessed the association between hormone therapy and venous 
thromboembolism among postmenopausal women. Oral but not transdermal 
estrogens were associated with an increased thrombotic risk. There was no 
significant association of venous thromboembolism with progesterone, pregnanes 
and nortestosterone. However, norpregnanes were associated with an increased 
thrombotic risk.  
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Despite recent data showing that overall health risks may exceed benefits from 
postmenopausal hormone therapy (HT) 1, 2, many women remain eligible for this 
treatment in order to correct menopausal symptoms 3, 4. However, harmful effects of 
HT may include breast cancer and venous thromboembolism 1, 5, 6. Recent guidelines 
recommend that women be prescribed the lowest effective dose of HT for the 
shortest possible duration 7, 8. Since the risk of venous thromboembolism is highest 
during the first year of treatment 9, 10, pulmonary embolism, which already 
represented one-third of the potentially fatal events attributable to long-term HT 11, 
has become one of the major side effects of short-term treatments. Reducing 
thrombotic risk may therefore have important clinical implications in the management 
of postmenopausal symptoms. Recent observational data have suggested that 
transdermal estrogens might be safe with respect to thrombotic risk 12, 13 but the 
impact of estrogens by route of administration is not fully established. In addition, 
data on the role of concomitant progestogens are scarce 13. Therefore, we 
investigated the impact of estrogens by route of administration as well as the 
influence of concomitant progestogens on the risk of idiopathic venous thrombosis in 
a large cohort of French women. 
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Methods 
 
E3N Study 
The E3N (Etude Epidémiologique de femmes de l’Education Nationale) Study is a 
prospective cohort study initiated in 1990 among 98,995 women born between 1925 
and 1950 and insured by a healthcare plan covering mostly teachers. Participants 
who gave written informed consent completed biennial self-administered 
questionnaires (sent between 1990 and July 2005) which included items about 
anthropometric measurements, medical history, menopausal status and a variety of 
lifestyle habits (e.g. contraceptive use, HT use, alcohol consumption, smoking). 
Details of the E3N design have been described elsewhere 14, 15. 
 
Ascertainment of venous thromboembolism cases 
Non-fatal venous thromboembolism events were initially self-reported by women in 
the questionnaires. Participants who declared to have had either a thrombosis or a 
pulmonary embolism were then asked to complete a specific questionnaire and to 
send medical documentation related to the thrombotic event. In addition, a 
questionnaire including information on potential predisposing factors for thrombosis 
and characteristics of the event was sent to the medical doctors reported by the 
women. In order to be validated, clinical events had to be diagnosed using an 
imaging procedure. Pulmonary embolism was defined as the presence of either a 
positive pulmonary angiography or a positive helicoidal computed tomography or a 
high-probability ventilation/perfusion lung scan. Deep venous thrombosis had to be 
diagnosed by use of compression ultrasonography or venography. Events were 
centrally validated by a medical committee blinded to HT use. Cases of fatal 
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pulmonary embolism were identified from death certificates from the National Service 
on Causes of Deaths (Inserm) using International Classification of Diseases (ICD) 9 
(codes 4151 and 4539) and ICD-10 (codes I26.0 and I26.9). In the present analysis, 
the main clinical outcome was a first documented incident episode of pulmonary 
embolism or lower-extremity deep vein thrombosis having occurred without any of the 
following predisposing factors, i.e. cancer, surgery, immobilization or trauma. 
Among the 98,995 women included in the E3N Study, 2,142 episodes of venous 
thromboembolism were self-reported during the overall follow-up. Among those, 
1,696 non-fatal thrombotic events were further validated and 446 were not 
considered as venous thromboembolism episode because they were not thrombotic 
events (n=149) or no information could be obtained (n=297). Superficial vein 
thrombosis (n=216), upper-extremity thrombosis (n=23), central retinal vein 
obstruction (n=2), and recurrent events (n=80) were also treated as non events which 
resulted in a total of 1,375 incident cases of non-fatal deep vein thrombosis or 
pulmonary embolism. In addition, 68 cases of fatal pulmonary embolism were 
identified by death certificates. Overall, 1,443 incident thrombotic cases (including 68 
deaths) were eligible for inclusion in the present study. 
 
Study sample and follow-up 
The present investigation was limited to postmenopausal women. Information on 
menopausal status was updated at each follow-up questionnaire. Women were 
considered postmenopausal if they had had 12 consecutive months without 
menstrual periods (unless due to hysterectomy), had undergone bilateral 
oophorectomy, had ever used HT, or self-reported that they were postmenopausal. 
Age at menopause was defined as age at last menstrual period (if cessation of 
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menstruation did not occur after hysterectomy); age at bilateral oophorectomy; or, in 
decreasing order of priority, self-reported age at menopause, age at HT initiation,, 
age at first occurrence of menopausal symptoms. If no information was available, age 
at menopause was assigned at 47 years if menopause was artificial, and at 51 years 
otherwise, because these ages corresponded to the respective median ages for 
artificial and natural menopause in the cohort.  
Follow-up started on the return date of the first questionnaire where women declared 
to be menopausal. Participants contributed person-years of follow-up until the date of 
death for fatal cases and, for other subjects, until the date of a venous 
thromboembolism event, the date of cancer diagnosis (other than basal cell skin 
cancer), the date of the last completed questionnaire or July 2005, whichever 
occurred first.  
From the full cohort, 12,471 women including 219 cases were excluded because they 
were not menopausal or had had a thrombotic event before the start of follow-up. Of 
the remaining 86,524 women, 5,822 were excluded from the analyses due to 
personal history of cancer other than basal cell carcinoma (n=213 cases including 30 
fatal events) or a non-idiopathic thrombotic event (n=329) or an event without 
information on predisposing factors (n=65 including 38 fatal pulmonary embolisms). 
In addition, 68 women with a validated thrombotic event were censored at the date of 
cancer diagnosis because of a validated cancer predating the thrombotic event.  
The final analysis was therefore performed on 80,308 postmenopausal women 
without personal history of thrombotic events or cancer before the start of follow-up. 
The study population included 549 incident events of first documented idiopathic 
venous thromboembolism (134 pulmonary embolisms and 415 deep vein 
thromboses). 
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Classification of HT 
The 1992 questionnaire inquired about lifetime use of HT. It was accompanied by a 
booklet and photos of available estrogens and progestogens mailed to all 
participants. For each treatment episode, women were asked to report information on 
brand name, age at first use and duration of treatment. Information on HT was 
updated from each of the subsequent questionnaires. 
Women were classified as current users if they had used HT at any time during the 3 
months prior to the date of completion of the questionnaire, otherwise they were 
considered as past users or never users. Current users of HT were classified 
according to estrogens by route of administration and to the type of concomitant 
progestogen. Route of estrogen administration included oral, transdermal (patch or 
gel). Other treatments included tibolone, vaginal treatments, injectable treatments, 
HT without any information regarding the route of estrogen administration, and 
estrogens combined with androgens. Most current users of oral and transdermal 
estrogens received 17-estradiol. Progestogens were categorized according to the 
progestogen North American Menopause Society (NAMS) classification 16 . Women 
were classified as users of either micronised progesterone, pregnane derivatives, 
norpregnane derivatives or nortestosterone derivatives. Pregnane derivatives 
included dydrogesterone, medrogestone, chlormadinone acetate, cyproterone 
acetate and medroxyprogesterone acetate. Norpregnane derivatives included 
nomegestrol acetate and promegestone. Nortestosterone derivatives were 
norethisterone acetate. 
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Statistical analysis  
HT exposure was taken into account as a time-dependent variable. In order to 
preserve the prospective nature of the study, exposure status declared at the 
completion of each questionnaire was maintained during the entire interval until 
completion of the following questionnaire (or until the end of follow-up). Since data on 
exposure were available from the 1992 questionnaire onward, exposure between 
1990 and 1992 was considered as “unknown” for all women. Cox proportional 
hazards models with age as the time-scale were used to estimate the hazard ratios 
(HR) and 95% confidence intervals (CI) for venous thromboembolism associated with 
HT. The HRs were adjusted for body-mass index (as a continuous variable), parity 
(total number of stillborn and live births as a continuous variable) education level (six 
ordered categories as continuous variable) and time-period (before or after 2003 in 
order to take into account the changes in HT use after the publication of the Women’s 
Health Initiative trial results). These potential confounders were chosen because they 
have been related to thrombotic risk (e.g., body-mass index and parity 17) or because 
they have been linked to HT exposure and might have an impact on thrombotic risk 
(e.g., education level and time-period). Women with missing data for a covariate were 
excluded from analyses including that covariate. 
Data were analyzed by classifying women according to HT use. The main effects of 
past use, current use of estrogens by route of administration (either oral, transdermal 
or other) and current use of concomitant progestogens (either micronized 
progesterone, pregnanes, norpregnanes or nortestosterones) were estimated in the 
same model with never use of HT as the reference group. Homogeneity of estimated 
HRs was tested among different pharmacological classes of concomitant 
progestogen and between molecules within the groups of pregnane and norpregnane 
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derivatives. Interactions between the effects of estrogens and concomitant 
progestogens were tested by using a multiplicative HR model. 
Stratified analyses were conducted by type of diagnosis (deep vein thrombosis or 
pulmonary embolism) and mortality.  
Statistical analyses were performed using SAS statistical software (version 9.1, SAS 
Institute Inc, Cary, NC, 2004).  
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Results 
 
Table 1 shows the general characteristics of the study population. Mean age at the 
beginning of follow-up was 54.0 years and women were followed for an average of 
10.1 years. At the beginning of follow-up, mean body-mass index was 22.6 kg/m² and 
nearly 18% of the women were overweight or obese. 
Table 2 shows the HRs of venous thromboembolism by type of HT. Women who had 
never taken any HT were used as the reference group (n=181 cases). Past users of 
HT had similar thrombotic risk as never users (adjusted HR=1.1; 95% CI: 0.8-1.5). 
There was no significant interaction between the route of estrogen administration 
(either oral or transdermal) and concomitant progestogens (either micronized 
progesterone, pregnane derivatives, norpregnane derivatives or nortestosterone 
derivatives) (p for interaction=0.62). After adjustment for potential confounders, oral 
but not transdermal estrogen use was associated with an increased risk of 
thrombosis (HR=1.7; 95% CI: 1.1-2.8 and HR=1.1; 95% CI: 0.8-1.8, respectively). In 
addition, among users, the hazard ratio was significantly increased in oral estrogen 
users as compared to transdermal estrogen users (HR=1.5; 95% CI: 1.1-2.0). 
Regarding the impact of concomitant progestogens, the test for homogeneity among 
pharmacological subgroups was statistically significant (p<0.01). However, no 
significant heterogeneity was found between molecules within the groups of 
pregnane and norpregnane derivatives (p=0.07 and p=0.17, respectively). There was 
no significant association of venous thrombosis with micronized progesterone and 
pregnane derivatives (HR=0.9; 95% CI: 0.6-1.5 and HR=1.3; 95% CI: 0.9-2.0, 
respectively). In addition, nortestosterone derivatives were not significantly 
associated with thrombotic risk (HR=1.3; 95% CI: 0.7-2.4). By contrast, norpregnane 
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derivatives were associated with an increased thrombotic risk (HR=1.8; 95% CI: 1.2-
2.7). 
Stratified analyses by type of diagnosis showed no striking differences in thrombotic 
risk associated with HT use between deep vein thrombosis and pulmonary embolism 
(data not shown).  
In the principal analysis, 65 of the validated cases were excluded because no 
information on predisposing factors was available. These cases included fatal 
pulmonary embolisms identified from death certificates which did not contain such 
information (n=38). Thus, additional analyses were performed with pooled idiopathic 
cases and cases without any information on predisposing factors (n=614). The 
inclusion of these cases did not substantially modify the results. Indeed, the hazard 
ratios of venous thromboembolism for oral and transdermal estrogens were 
respectively 1.6 (95% CI 1.0-2.4) and 1.1 (95% CI 0.8-1.6). Using this same study 
sample, an additional analysis restricted to non-fatal events (n=576) led to similar 
results (data not shown). 
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Discussion 
 
These findings suggest that the route of estrogen administration and the type of 
concomitant progestogen are both important determinants of thrombotic risk among 
postmenopausal women who use HT. Transdermal estrogens may be safe when 
they are administrated alone or along with micronized progesterone but not with 
norpregnane derivatives. By contrast, oral estrogens are associated with an 
increased thrombotic risk irrespective of the presence of concomitant progestogens.  
Our results regarding oral estrogen therapy are in agreement with those from both 
observational studies and clinical trials which have shown that oral estrogens were 
thrombogenic 9, 18. Thus far, only four studies have investigated the impact of 
transdermal estrogens on the risk of venous thrombosis 12, 19-21. A combined analysis 
of these studies yielded an overall odds ratio close to one in transdermal estrogen 
users compared to non-users 9. Our results showing no increased thrombotic risk 
among women who use transdermal estrogens alone are consistent with this 
previous report.  
While some previous studies have focused on the estrogens by route of 
administration, few data are available regarding the impact of concomitant 
progestogens by pharmacological classes on the risk of venous thromboembolism. 
On one hand, some observational studies 19-23 and one clinical trial 24 have compared 
the risk of venous thromboembolism between users of estrogens alone and users of 
estrogens combined with progestogens. Overall, these results showed that oral 
estrogens combined with progestogens could be more thrombogenic than oral 
estrogens alone 9. In addition, a comparison of both Women’s Health Initiative trials 
also suggested that the risk of thrombosis was higher among users of opposed 
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estrogens than among users of estrogens alone 1, 2, 5, 6. On the other hand, the 
ESTHER case-control study recently investigated the impact of concomitant 
progestogens by pharmacological classes 13. In this study, micronized progesterone 
and pregnane derivatives were not significantly associated with an increased risk of 
venous thromboembolism, while norpregnane derivatives were thrombogenic 
compared to non-use. The present findings regarding micronized progesterone and 
norpregnane derivatives are consistent with these previous results. Finally, to our 
knowledge, the E3N study is the first to assess thrombotic risk in relation to 
nortestosterone derivatives used in HT and only few data are available on the effect 
of nortestosterones used alone. Although not statistically significant, the increased 
thrombotic risk associated with combined use of nortestosterones and estrogens in 
the E3N study can be paralleled with the elevated thrombotic risk observed in 
premenopausal women who received nortestosterone derivatives alone 25. However, 
the limited number of cases exposed to nortestosterone derivatives in our study did 
not allow assessing the effect estimates with sufficient statistical power.   
 
The potential mechanisms underlying the increase in thrombotic risk among users of 
specific treatments include a prothrombotic state, a decrease in blood flow and/or an 
alteration of the vessel wall 26, 27. Since 1997, several studies have shown that oral 
but not transdermal estrogens activate blood coagulation and induce an activated 
protein C resistance, providing a biological evidence to support the difference in 
thrombotic risk by route of estrogen administration 28-33. In some of the studies, oral 
and transdermal estrogens were both combined with micronized progesterone. 
These haemostatic data, together with the results of both the ESTHER 13 and the 
E3N studies, support the potential safety of transdermal estrogens combined with 
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micronized progesterone. Data on the effect of progestogens on haemostasis are 
scarce and results remain inconsistent. One study has shown that a pregnane 
derivative had little to no effect on haemostasis 34. Moreover, several trials have 
failed to show any changes in levels of haemostatic parameters between 
progestogen subgroups 35-38. Nevertheless, recent data suggested that trimegestone, 
a norpregnane derivative, had a stronger effect on fibrinolysis inhibition as compared 
to dydrogesterone 39. Thus, whether or not progestogens have differential effects on 
haemostasis requires further investigation.  
The increase in thrombotic risk among postmenopausal women using some 
progestins could also be mediated by changes in venous structure and function 27. 
The occurrence of venous stasis, especially observed during pregnancy and the 
luteal phase, could be modulated by steroid sex hormones via progesterone 
receptors which are present in the venous wall 40. Therefore, an increase in 
progestational activity of progestins, especially norpregnanes, compared to 
micronized progesterone might further alter blood flow and increase thrombotic risk.   
 
One potential limitation of the E3N prospective cohort study is that, as an 
observational study, it is subject to bias. Several types of bias have already been 
discussed 14, 15. In the present analysis, potential limitations include how selected the 
population was, why women were prescribed a specific treatment, misclassification 
regarding diagnosis and/or exposure and potential confounders in the statistical 
analysis. First, women recruited in the E3N study were mostly teachers and could 
represent a health-conscious population which might be at lesser risk than the 
general population. However, it is unlikely that this non-differential selection of 
healthy subjects could affect the comparison between users and non-users of HT. 
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Second, an indication bias might have occurred due to differential prescription of 
concomitant progestogens according to the estrogenic status of women using HT. 
Norpregnane derivatives are potent progestogens with anti-estrogenic activity. 
Women with moderate to severe hyperestrogenic symptoms, such as breast 
tenderness or endometrial diseases, may be more likely to be prescribed these types 
of progestogen 41, 42. Since there is evidence that lifetime estrogen exposure is 
positively related to venous thromboembolism in postmenopausal women 17, this 
prescription bias could partly explain the increase in thrombotic risk among women 
using such anti-estrogenic progestogens.  
Another limitation of our cohort study is that HT use was self-reported and non-
differential misclassifications regarding exposure might have occurred during follow-
up. The effect of such errors is to decrease the strength of the observed associations 
towards the null. This limitation could explain the lower relative risks observed in our 
study compared to previous findings 9 . We also cannot rule out a potential non-
detected relationship between some treatments which appear safe and thrombotic 
risk. Another possible dilution of risk estimates may result from our definition of 
exposure. We used hormonal exposure declared at the beginning of each follow-up 
interval for the entire interval until the following subsequent questionnaire. This 
strategy allowed preserving the prospective nature of the study and avoiding 
differential recall bias between cases and non-cases. However, such exposure 
classification might lead to an incomplete capture of exposed cases, especially for 
those who started their treatment just after the date of questionnaire completion. 
Further, potential confounders including elevated levels of thrombotic risk factors 
could explain our findings related to the effects of estrogens by route of 
administration and concomitant progestogens. Although some thrombotic risk factors, 
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such as prothrombotic mutations or family history of venous thromboembolism, were 
not measured in this study, adjustment for other predisposing factors for thrombosis, 
such as body-mass index or parity, did not appreciably change the results. The 
unavailable information on estrogens doses was also a limitation of our study. While 
increasing doses of estrogens may increase the coagulation activation 43, 
observational studies have suggested no significant difference in thrombotic risk by 
estrogen dose 12, 19, 20, 22, 23. However, studies with high level of evidence comparing 
estrogen doses effect on thrombotic risk are still lacking. 
Finally, our analysis was restricted to idiopathic venous thromboembolism because 
inclusion of cases with predisposing factors might have attenuated the associations 
between hormone use and thrombotic risk.  In addition, it is likely that the presence of 
predisposing factors for venous thromboembolism could modify hormone exposure. 
Therefore, analysis restricted to idiopathic cases provides more accurate estimates of 
thrombotic risk. Nonetheless, this selection criterion did not allow extrapolating our 
results to secondary events.   
The E3N cohort study also has several strengths including its prospective, 
population-based design as well as its large number of participants. In addition, 
follow-up questionnaires sent biennially starting from 1990 allow for the frequent 
update of information on menopausal status and HT use. In the present ancillary 
study, a further strength is the large number of well documented incident cases of 
venous thromboembolism.  
 
Our findings regarding the impact of estrogens by route of administration and 
concomitant progestogens on thrombotic risk may have important clinical 
implications. Since pulmonary embolism has become a major determinant of the 
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benefit/risk ratio of short-term oral estrogen therapy, reducing the risk of venous 
thromboembolism could substantially improve the benefit/risk profile of HT. 
Therefore, short-term use of transdermal estrogens alone or combined with 
progesterone could be a good option in the management of postmenopausal 
symptoms. However, further data are needed and the present results should be 
confirmed with randomized controlled trials.  
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Table 1. General characteristics of the study population at the beginning of follow-up. 
The E3N Cohort. 
 
Characteristics  Population (n=80,308) 
     
Age at entry (years)  54.0 (4.3) 
   
Follow-up (years)  10.1 (4.6) 
   
Body-mass index (kg/m²)  22.6 (3.2) 
   
Overweight (25≤BMI<30 kg/m²)  11,808 (14.6) 
   
Obesity (BMI≥30 kg/m²)  2,483 (3.1) 
   
Current smokers  7,095 (9.9) 
   
High school graduate  66,002 (83.1) 
   
Age at menopause (years)  50.2 (3.8) 
   
Hysterectomy  16,257 (20.2) 
   
Parity  2.2 (0.9) 
   
Past use of oral contraceptives  46,387 (57.8) 
      
   
Values are mean (SD) or number (%)   
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Table 2. Hazard ratios of idiopathic venous thromboembolism in relation to both 
estroges by route of administration and concomitant progestogens. 
 
Treatment 
 
cases 
  
Person-
Years 
 
Hazard Ratios (95% confidence 
intervals) 
   Age-adjusted 
Multivariable 
adjusted * 
  n=549  811643    
             
        
Never use  181  291399  1 [reference] 1 [reference] 
           
        
Past use  66  100943  1.0 (0.7-1.3) 1.1 (0.8-1.5) 
          
        
Current use of oral estrogens  81  93211  1.5 (0.9-2.3) 1.7 (1.1-2.8) 
        
Current use of transdermal estrogens  174  268481  1.1 (0.7-1.6) 1.1 (0.8-1.8) 
          
        
No progestogens use  26  46163  - - 
        
Current use of micronised progesterone  47  87959  0.9 (0.6-1.4) 0.9 (0.6-1.5) 
        
Current use of pregnane derivatives  91  125804  1.3 (0.8-1.9) 1.3 (0.9-2.0) 
        
Current use of norpregnane derivatives  69  78855  1.7 (1.1-2.6) 1.8 (1.2-2.7) 
        
Current use of nortestosterone derivatives  22  22911  1.4 (0.8-2.5) 1.4 (0.7-2.4) 
          
        
Current use of other treatment  30  47693  1.0 (0.7-1.5) 1.1 (0.7-1.8) 
        
Unknown  17  9916  2.0 (0.5-3.9) 2.0 (0.5-3.9) 
             
      
      
* Adjusted for age, body-mass index, parity, education level and time-period 
Data for adjustment missing for 19 cases and for 843 non-cases 
 
      
p for homogeneity between current use of oral estrogens versus current use of transdermal estrogens is 
significant (p=0.01) 
p for homogeneity between progestogen subgroups is significant (p<0.01)  
      
 
 
 
 
 
